Optimal adjuvant chemotherapy in breast cancer: Selection of agents

Research output: Contribution to journalArticlepeer-review


Historically, the selection of the most effective adjuvant regimen for breast cancer patients was based on tumor size and nodal status but this approach took into account the stage only, without considering that the biology of the tumor matters as well, as breast cancer is a heterogeneous disease at the molecular level. In the present manuscript we will attempt to address the issue of selecting the most appropriate cytotoxic agents for adjuvant programs in the clinically and biologically distinct subgroups of endocrine responsive (luminal A and luminal B), HER2 positive and triple negative breast cancer patients.

Original languageEnglish
Pages (from-to)605-611
Number of pages7
JournalExpert Review of Clinical Pharmacology
Issue number5
Publication statusPublished - 2014


  • breast cancer
  • chemotherapy
  • predictive factor
  • subtype

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Medicine(all)


Dive into the research topics of 'Optimal adjuvant chemotherapy in breast cancer: Selection of agents'. Together they form a unique fingerprint.

Cite this